



Fundamentals of Medicinal Chemistry

Gareth Thomas

 WILEY

Contents

Preface	xi
Acknowledgements	xii
Abbreviations/Acronyms	xiii
1 Biological Molecules	1
1.1 Introduction	1
1.2 Amino acids	1
1.2.1 Introduction	1
1.2.2 Structure	3
1.2.3 Nomenclature	3
1.3 Peptides and proteins	4
1.3.1 Structure	6
1.4 Carbohydrates	10
1.4.1 The structure of monosaccharides	11
1.4.2 The nomenclature of monosaccharides	14
1.4.3 Glycosides	15
1.4.4 Polysaccharides	17
1.4.5 The nomenclature of polysaccharides	18
1.4.6 Naturally occurring polysaccharides	18
1.5 Lipids	20
1.5.1 Introduction	20
1.5.2 Fatty acids	20
1.5.3 Acylglycerols (glycerides)	21
1.5.4 Steroids	21
1.5.5 Terpenes	22
1.5.6 Phospholipids	23
1.5.7 Glycolipids	25
1.6 Nucleic acids	26
1.6.1 Introduction	26
1.6.2 DNA, structure and replication	28
1.6.3 Genes and the human genome project	30
1.6.4 RNA, structure and transcription	31
1.6.5 Classification and function of RNA	33
1.7 Questions	34
2 An Introduction to Drugs and their Action	37
2.1 Introduction	37
2.2 What are drugs and why do we need new ones?	37
2.3 Drug discovery and design, a historical outline	39
2.4 Sources of drugs and lead compounds	43

2.4.1	Natural sources	43
2.4.2	Drug synthesis	45
2.4.3	Market forces and 'me-too drugs'	45
2.5	Classification of drugs	45
2.6	Routes of administration, the pharmaceutical phase	46
2.7	Introduction to drug action	49
2.7.1	The pharmacokinetic phase	49
	Absorption	49
	Distribution	50
	Metabolism	51
	Elimination	51
2.7.2	Bioavailability of a drug	53
2.7.3	The pharmacodynamic phase	53
2.8	Questions	55
3	An Introduction to Drug Discovery	57
3.1	Introduction	57
3.2	Stereochemistry and drug design	59
3.2.1	Structurally rigid groups	59
3.2.2	Conformation	60
3.2.3	Configuration	60
3.3	Solubility and drug design	61
3.3.1	The importance of water solubility	62
3.4	Solubility and drug structure	63
3.5	Salt formation	64
3.6	The incorporation of water solubilizing groups in a structure	65
3.6.1	The type of group	66
3.6.2	Reversibly and irreversibly attached groups	66
3.6.3	The position of the water solubilizing group	67
3.6.4	Methods of introduction	67
3.7	Questions	70
4	The SAR and QSAR Approaches to Drug Design	71
4.1	Structure-activity relationships (SARs)	71
4.2	Changing size and shape	73
4.3	Introduction of new substituents	73
4.3.1	The introduction of a group in an unsubstituted position	73
4.3.2	The introduction of a group by replacing an existing group	76
4.4	Quantitative structure-activity relationships (QSARs)	78
4.4.1	Lipophilicity	79
	Partition coefficients (P)	79
	Lipophilic substitution constants (π)	80
4.4.2	Electronic effects	82
	The Hammett constant (σ)	82
4.4.3	Steric effects	83
	The Taft steric parameter (E_s)	84
	Molar refractivity (MR)	84
	Other parameters	85

4.4.4	Hansch analysis	85
	Craig plots	88
4.5	The Topliss decision tree	89
4.6	Questions	92
5	Computer Aided Drug Design	95
5.1	Introduction	95
	5.1.1 Molecular modelling methods	96
	5.1.2 Computer graphics	98
5.2	Molecular mechanics	98
	5.2.1 Creating a molecular model using molecular mechanics	102
5.3	Molecular dynamics	104
	5.3.1 Conformational analysis	105
5.4	Quantum mechanics	105
5.5	Docking	109
5.6	Questions	110
6	Combinatorial Chemistry	113
6.1	Introduction	113
	6.1.1 The design of combinatorial syntheses	115
	6.1.2 The general techniques used in combinatorial synthesis	116
6.2	The solid support method	117
	6.2.1 Parallel synthesis	118
	6.2.2 Furka's mix and split technique	121
6.3	Encoding methods	123
	6.3.1 Sequential chemical tagging methods	123
	6.3.2 Still's binary code tag system	124
	6.3.3 Computerized tagging	126
6.4	Combinatorial synthesis in solution	127
6.5	Screening and deconvolution	128
6.6	Questions	130
7	Selected Examples of Drug Action at some Common Target Areas	131
7.1	Introduction	131
7.2	Examples of drugs that disrupt cell membranes and walls	131
	7.2.1 Antifungal agents	132
	Azoles	133
	Allylamines	134
	Phenols	135
	7.2.2 Antibacterial agents	135
	Ionophoric antibiotic action	135
	Cell wall synthesis inhibition	136
7.3	Drugs that target enzymes	138
	7.3.1 Reversible inhibitors	139
	7.3.2 Irreversible inhibition	140
	7.3.3 Transition state inhibitors	142
7.4	Drugs that target receptors	144
	7.4.1 Agonists	144
	7.4.2 Antagonists	145
	7.4.3 Partial agonists	147

7.5	Drugs that target nucleic acids	147
7.5.1	Antimetabolites	147
7.5.2	Enzyme inhibitors	150
7.5.3	Intercalation agents	151
7.5.4	Alkylating agents	152
7.5.5	Antisense drugs	152
7.5.6	Chain cleaving agents	154
7.6	Antiviral drugs	155
7.6.1	Nucleic acid synthesis inhibitors	155
7.6.2	Host cell penetration inhibitors	156
7.6.3	Inhibitors of viral protein synthesis	157
7.7	Questions	157
8	Pharmacokinetics	159
8.1	Introduction to pharmacokinetics	159
8.1.1	General classification of pharmacokinetic properties	160
8.2	Pharmacokinetics and drug design	160
8.3	Pharmacokinetic models	161
8.4	Intravascular administration	162
8.4.1	Intravenous injection (IV bolus)	163
8.4.2	Clearance and its significance	166
8.4.3	Intravenous infusion	169
8.5	Extravascular administration	171
8.5.1	Single oral dose	174
8.5.2	The calculation of t_{max} and C_{max}	176
8.5.3	Repeated oral doses	176
8.6	The use of pharmacokinetics in drug design	177
8.7	Questions	178
9	Drug Metabolism	181
9.1	Introduction	181
9.1.1	The stereochemistry of drug metabolism	181
9.1.2	Biological factors affecting metabolism	183
9.1.3	Environmental factors affecting metabolism	184
9.1.4	Species and metabolism	184
9.2	Secondary pharmacological implications of metabolism	184
9.3	Sites of action	184
9.4	Phase I metabolic reactions	186
9.4.1	Oxidation	186
9.4.2	Reduction	186
9.4.3	Hydrolysis	189
9.4.4	Hydration	189
9.4.5	Other Phase I reactions	189
9.5	Phase II metabolic routes	190
9.6	Pharmacokinetics of metabolites	190
9.7	Drug metabolism and drug design	193
9.8	Prodrugs	195
9.8.1	Bioprecursor prodrugs	195
9.8.2	Carrier prodrugs	196

9.8.3 The design of prodrug systems for specific purposes	197
Improving absorption and transport through membranes	197
Improving patient acceptance	198
Slow release	198
Site specificity	198
Minimizing side effects	200
9.9 Questions	200
10 An Introduction to Lead and Analogue Syntheses	203
10.1 Introduction	203
10.2 Asymmetry in syntheses	205
10.2.1 The use of non-stereoselective reactions to produce stereospecific centres	206
10.2.2 The use of stereoselective reactions to produce stereospecific centres	207
10.2.3 General methods of asymmetric synthesis	208
Methods that use catalysts to obtain stereoselectivity	210
Methods that do not use catalysts to obtain stereoselectivity	211
10.3 Designing organic syntheses	214
10.3.1 An introduction to the disconnection approach	214
10.4 Questions	220
11 Drug Development and Production	223
11.1 Introduction	223
11.2 Chemical development	224
11.2.1 Chemical engineering issues	225
11.2.2 Chemical plant, health and safety considerations	226
11.2.3 Synthesis quality control	227
11.2.4 A case study	228
11.3 Pharmacological and toxicological testing	231
11.4 Drug metabolism and pharmacokinetics	234
11.5 Formulation development	235
11.6 Production and quality control	235
11.7 Patent protection	236
11.8 Regulation	237
11.9 Questions	238
Appendix	239
A.1 Sickle-cell anaemia	239
A.2 Bacteria	240
A.3 Cell membranes	244
A.4 Receptors	246
A.5 Transfer through membranes	249
A.6 Regression analysis	250
A.7 Enzymes	252

A.8 Prostaglandins	255
A.9 Cancer	256
A.10 Viruses	257
A.11 Blood-brain barrier	259
A.12 Enzyme structure and species	260
Answers to Questions	261
Selected Further Reading	273
Index	275